Active Biotech invites to Capital Markets Day

May 29, 2012 13:00 (CEST)

Active Biotech invites analysts, investors and media to Capital Markets Day on June 14, 2012.

When:              Thursday, June 14, 2012 at 2-4 p.m. CET.

Where:             Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm, Sweden.  

To attend:         Please send name & contact details to or call +46 (0)46 19 20 00,
no later than June 10, 2012.

Active Biotech participants:
                        Tomas Leanderson, President & CEO
                        Göran Forsberg, Chief Business Officer
Program:          Overview of Active Biotech's project portfolio

The Capital Markets Day will also be available to follow via Active Biotech's website

For further information, please contact:
Hans Kolam, CFO
Phone: +46 (0)46 19 20 44

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for Systemic Sclerosis and RhuDex® for RA. Please visit for more information.


Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00    


Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication 1:00 p.m. CET on May 29, 2012.

Active Biotech invites to Capital Markets Day